Silodosin 4mg versus tamsulosin 0.2mg once daily; randomized crossover study
Not Applicable
- Conditions
- Benign prostate hyperplasia
- Registration Number
- JPRN-UMIN000004918
- Lead Sponsor
- Saitama Red Cross Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who took alfa 1 blocker within 28 days; patients who were taking phosphodiesterase 5 inhibitor, 5 alfa reductase inhibitor and antiandrogen; patients with severe renal disfunction (eGFR<30ml/min/1.73m2); or patients who were judged to be inappropirate by physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method International prostate symptom score (IPSS), overactive bladder symptom score, quality of life (QOL) score
- Secondary Outcome Measures
Name Time Method roflowmetry, blood pressure, male sexual function